News

For people with hard-to-treat cold agglutinin disease (CAD), long-term treatment with Enjaymo (sutimlimab-jome) may offer lasting disease control, even with less frequent infusions than recommended, according to a small real-world study in Italy. Enjaymo was found to quickly reduce red blood cell destruction, ease anemia, and eliminate the need…

Rituximab plus glucocorticoids led to sustained disease remission in an older woman who developed cold agglutinin disease (CAD) and severe kidney disease after receiving long-term immunosuppressive treatment for two other autoimmune diseases, a study shows. “Rituximab combined with glucocorticoids led to a prompt and marked improvement in anemia…

Rituximab helped improve signs and symptoms of cold agglutinin disease (CAD) occurring alongside acquired hemophilia A, another autoimmune blood disorder, in a 53-year-old man in China, a case report describes. In CAD, the immune system mistakenly attacks red blood cells, while in acquired hemophilia A, it targets factor…

A new case series urges clinicians to keep cold agglutinin disease (CAD) on their radar when treating elderly patients with unexplained anemia. Researchers say that because the rare autoimmune condition often occurs with “clinically subtle” or atypical symptoms, it can easily be missed, delaying essential treatment for underlying causes…

The U.S. Food and Drug Administration (FDA) has granted fast-track designation to Ouro Medicines’ experimental treatment gamgertamig for autoimmune hemolytic anemia (AIHA), a group of autoimmune diseases that includes cold agglutinin disease. Fast-track designation is intended to accelerate the development and review of potential treatments for serious diseases…

People with cold agglutinin disease (CAD) treated long-term with Enjaymo (sutimlimab-jome) maintained stable hemoglobin levels, avoided blood transfusions, and showed sustained reductions in red blood cell destruction for nearly two years, according to a real-world, single-center study from Germany. “The present small, [single-center]…

A man and a woman in China were found to have a type of fast-growing blood cancer called diffuse large B-cell lymphoma (DLBCL) as the underlying cause of their autoimmune hemolytic anemia (AIHA), a group of disorders in which the immune system attacks and destroys red blood cells, according to…

A short course of rituximab, combined with chemotherapy agents and corticosteroids, can keep primary cold agglutinin disease (CAD) under control for many years, at a lower cost and with manageable side effects, according to a study of seven patients in Japan. “Rituximab-based chemoimmunotherapy elicited durable responses with an…

A combination of chemotherapy and immune-targeting medications may provide long-lasting relief for people with cold agglutinin disease (CAD), though the treatment often comes with a high risk of serious side effects, according to real-world patient data. These “immunochemotherapy” (ICT) regimens, specifically those using R-bendamustine, have shown significant success in normalizing…

The oral medication iptacopan — approved for certain blood and complement-related conditions — helped alleviate anemia in most people with cold agglutinin disease (CAD) in a small Phase 2 clinical trial, according to study. The complement cascade is a component of the immune system that contributes to the hemolysis,…